NCT02943343: CURES

The China Pulmonary Thromboembolism Registry Study

Status unknown Last updated 26 August 2020

What this trial tests

trial testing No intervention in Pulmonary Embolism in 15,000 participants. Status unknown.

Timeline

1 January 2009

Primary endpoint
31 December 2020

31 December 2025

Quick facts

Lead sponsor	China-Japan Friendship Hospital
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	15,000
Start date	1 January 2009
Primary completion	31 December 2020
Estimated completion	31 December 2025
Sites	1 location across China

Drugs / interventions tested

• No intervention

Conditions studied

• Pulmonary Embolism — all drugs for Pulmonary Embolism →
• Deep Venous Thrombosis — all drugs for Deep Venous Thrombosis →
• Venous Thromboembolism — all drugs for Venous Thromboembolism →

Sponsor

China-Japan Friendship Hospital

Who can join

18 and older, any sex, with Pulmonary Embolism or Deep Venous Thrombosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Epidemiological data on pulmonary embolism (PE) in China needs to be updated and reported. The China Pulmonary Thromboembolism Registry Study (CURES) is designed to provide the cross-sectional spectrum and chronological trends of PE in China, as well as to reveal the intrinsic etiology and pathogenesis of the disease. The CURES is an ongoing large prospective multicenter registry, which was originally initiated in January 2009 via enrolling suspected or confirmed PE or PE with DVT (deep venous thrombosis) patients and assessed their in-hospital outcomes from 100 medical centers in the China PE-DVT network. As of July 2011, in order to determine the PE-relevant short-term outcomes, enrolled participants were followed-up for at least three months in a longitudinal manner. Since August 2016, with the launch and development of precision medicine research scheme in China, the main principle investigators of CURES decided to collect enrolled patients' blood samples with regular follow-ups every three or six months for at least two years (for long-term outcomes). The study protocol has been approved by the China-Japan Friendship Hospital ethics committee, and all collaborating centers received approvals from their local ethics committee. All patients provided written or verbal informed consent to their participation.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

1. Rational and design of the China Pulmonary Thromboembolism Registry Study (CURES): A prospective multicenter registry.
   Lei J, Xu X, Ji Y, Yang Y, et al · · 2020 · cited 10× · PMID 32522676 · DOI 10.1016/j.ijcard.2020.05.087
2. LMWHs dosage and outcomes in acute pulmonary embolism with renal insufficiency, an analysis from a large real-world study.
   Wang D, Fan G, Lei J, Yang Y, et al · · 2022 · cited 5× · PMID 35513826 · DOI 10.1186/s12959-022-00385-z
3. Clinical Phenotypes With Prognostic Implications in Pulmonary Embolism Patients With Syncope.
   Zhang S, Xu X, Ji Y, Yang Y, et al · · 2022 · cited 5× · PMID 35242828 · DOI 10.3389/fcvm.2022.836850
4. Clinical characteristics and mortality predictors among very old patients with pulmonary thromboembolism: a multicenter study report.
   Zhou X, Yang Y, Zhai Z, Wang D, et al · · 2024 · cited 3× · PMID 38200493 · DOI 10.1186/s12890-023-02824-7
5. Performance of Bleeding Risk Scores for Major Bleeding in Anticoagulated Patients with Pulmonary Embolism: Insights from the CURES Registry-2.
   Tao Y, Chen H, Dong C, Zhang J, et al · · 2026 · cited 2× · PMID 40555360 · DOI 10.1055/a-2642-0241
6. Cardiometabolic multimorbidity and short-term outcomes in pulmonary embolism: Findings from the CURES Registry-2.
   Li H, Zhang Y, Chen Y, Chen H, et al · · 2026 · PMID 41624048 · DOI 10.1016/j.ajpc.2026.101419